• News
  • North America

Kernal Bio Secures IFLI Investment for KR-402

Funding complements an ARPA-H award of up to US$48 million and new leadership appointments.

11/17/2026
•Ghita Khalfaoui
Back to News

Kernal Bio has received a strategic investment from the Institute for Follicular Lymphoma Innovation to support KR-402. The investment follows an award of up to US$48 million from ARPA-H for the same program. Kernal Bio develops mRNA-based treatments that program cells inside the body using targeted lipid nanoparticles.


Funding and partners

The IFLI investment is expected to accelerate preclinical development of KR-402. It adds to non-dilutive funding from ARPA-H and support from NVIDIA, Microsoft, and Eli Lilly. Kernal Bio also works within the Lilly Gateway Labs accelerator.

Leadership and board

Kirsten Kester joined the company as Chief Business Officer. Sieun K. Barnes joined as Director of Process Development for CMC. Stuart Chaffee became a director, while Carol O’Hear and Patrick Lundgren joined as board observers.

How the platform works

KR-402 is an mRNA-encoded CAR-T candidate for B-cell malignancies and autoimmune diseases. It uses the company’s mRNA 2.0 platform to generate CAR-T cells directly in the body. The system combines cell-selective mRNAs with antibody-coated lipid nanoparticle delivery.


Kernal Bio is working to advance KR-402 toward the clinic. The company also announced new advisors in immunology, rheumatology, neurology, finance, and business development. Its research is funded in part by ARPA-H under the EMBODY program.